Palomar/Gillette deal enters phase two:
This article was originally published in Clinica
Palomar Medical Technologies and Gillette have embarked on the second phase of a joint effort to develop and commercialise a patented home-use, light-based hair removal device for women. Palomar, of Burlington, Massachusetts, will disclose further information on proprietary optical hair-removal technology to assist in the research and Boston-based Gillette, following an amendment to the original agreement, will provide an additional $2.1m in development funding. The financing will be spread over a nine-month extension of the development phase, which is expected to be completed by August 31 2006.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.